The Rationality of Resectional Surgery and Palliative Interventions in the Management of Patients with Gallbladder Cancer. Issue 6 (June 2015)

• Record Type: Journal Article
• Authors: Ercan, Metin; Bostanci, Erdal B.; Cakir, Tebessum; Karaman, Kerem; Ozer, Ilter; Ulas, Murat; Dalgic, Tahsin; Ozogul, Yusuf; Aksoy, Erol; Akoglu, Musa
• Is Part Of: American surgeon. Volume 81:Issue 6(2015)
• Page Start: 591
• Page End: 599
• Publication Date: 2015-06
• Subjects: Surgery -- Periodicals; Surgery -- United States -- Periodicals; 617.0973
• DOI: 10.1177/000313481508100623
• Languages: English
• ISSNs: 0003-1348

Abstract

The aim of the present study was to evaluate in a retrospective manner, the survival period and survival rate according to stages and groups after R0, R1, R2 resections and palliative interventions. Between 2003 and 2012, 67 patients diagnosed with gallbladder carcinoma were retrospectively analyzed. Patient demographics, the survival period, and survival rate according to stages and groups after R0, R1, R2 resections and palliative interventions were retrospectively analyzed. Sixty-seven patients were diagnosed with gallbladder carcinoma. Thirty-eight patients (56.7%) were female and 29 patients (43.3%) were male. The median survival period was significantly longer in stage II and III diseases than in stage IV disease ( P < 0.001). The R0, R1, and R2 resection rates in patients who underwent surgery with curative intent were 67.7, 19.4, and 12.9 per cent, respectively. The R0 resection rate according to the tumor stages was 100 per cent for stage I, 87.5 per cent for stage II, 66.7 per cent for stage III, and 42.8 per cent for stage IV disease. The median follow-up period was six months (eight days to 36 months). During this follow-up period, 53 patients (79.1%) died. In conclusion, R0 resection rate decreases when tumor stage increases. The highest survival rates after R0 resection are achieved in patients with stage I, II, and III diseases. Radical surgery has no benefit over palliative surgery for stage IV disease in terms of survival.